GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
=== 2 May === Russia claimed to have taken Berdychi, near Avdiivka. It also claimed to have shot down a drone over Crimea. Two people were killed in separate Russian attacks in Donetsk and Kharkiv Oblasts.
The microbiome is a microbial community occupying a well-defined habitat with distinct physio-chemical properties. It includes the microorganisms involved and their theatre of activity, forming ecological niches. Microbiomes form dynamic and interactive micro-ecosystems prone to spaciotemporal change. They are integrated into macro-ecosystems, such as eukaryotic hosts, and are crucial to the host's proper function and health. The interactive host-microbe systems make up the holobiont. Microbiomics is the study of microbiome dynamics, function, and structure. This area of study employs several techniques to study the microbiome in its host environment:
Epidemiologists and public health officials use these models for several critical purposes: analyzing disease transmission dynamics, projecting the total number of infections and recoveries over time, estimating key epidemiological parameters such as the basic reproduction number (R0) or effective reproduction number (Rt), evaluating potential impacts of different public health interventions before implementation, and informing evidence-based policy decisions during disease outbreaks. Beyond infectious disease modeling, the approach has been adapted for applications in population ecology, pharmacokinetics, chemical kinetics, and other fields requiring the study of transitions between defined states. For such investigations and to consult decision makers, often more complex models are used.
=== Rejuva === Rejuva is an adeno-associated virus (AAV)-based gene therapy platform to enable the pancreas to produce GLP-1 on an ongoing basis as a treatment for obesity and type 2 diabetes. The therapy targets dysfunctional beta islet cells in the pancreas. Delivery is done with a needle catheter to deliver viral vectors into the pancreas. In January 2025, Rejuva completed Clinical Trial Application-enabling preclinical in vivo studies, beginning its first-in-human studies in the first half of 2025.
Sources: en.wikipedia.org
The Armenian-American radiologist Mihran Krikor Kassabian (1870-1910), vice president of the American Roentgen Ray Society (ARRS), was concerned about the irritating effects of X-rays. In a publication, he mentioned his increasing problems with his hands. Although Kassabian recognized X-rays as the cause, he avoided making this reference so as not to hinder the progress of radiology. In 1902, he suffered a severe radiation burn on his hand. Six years later, the hand became necrotic and two fingers of his left hand were amputated. Kassabian kept a diary and photographed his hands as the tissue damage progressed. He died of cancer in 1910.
== History and Development == Tagging technology and instrument development occurred at the University of Toronto and DVS Sciences, Inc. CyTOF (cytometry by time of flight) was initially commercialized by DVS Sciences in 2009. In 2014, Fluidigm acquired DVS Sciences to become a reference company in single cell technology. The technology evolved through models like CyTOF, CyTOF2, Helios (CyTOF3) and CyTOF XT, with the latter announced in 2021. In 2022 Fluidigm received a capitol infusion and changed its name to Standard BioTools. In 2023, Standard BioTools introduced the Hyperion XTi Imaging System, advancing Imaging Mass Cytometry (IMC) with capabilities such as whole slide imaging, automated sample processing, and dual imaging/flow cytometry modes. In 2024, the company expanded its high-throughput imaging options with two additional rapid modes and an automated slide loader that can be installed directly on the Hyperion XTi for automatic loading and acquisition of up to 40 slides. Additionally, a 2024 collaboration with Navignostics was announced to develop clinical research applications using the Hyperion XTi system . In 2025, Standard BioTools announced the CyTOF XT Pro System, streamlining workflow with up to 4x faster throughput and software with 21 CFR Part 11 compliance enabling features.
=== Pharmacodynamics === The mechanism of action of tiflorex has apparently never been studied. Similar compounds such as fenfluramine, norfenfluramine and 4-MTA act as selective serotonin releasing agents and 5-HT2 receptor agonists. Fenfluramine in particular causes very similar side effects and appetite suppression at therapeutically relevant doses.
=== 2012: Deaths of senior staff === On 19 November 2012, the senior staff members Jorge Ivan Arango Herrera and Carl Magnus Lindgren were killed on Chai Wan Road, Hong Kong, when their taxi was hit by two buses. The taxi driver, Wong Kim-chung, was also killed, and a further 56 people were injured.
Murphree developing centrifuges, and Arthur Compton responsible for theoretical studies and design. On 23 April 1942, Met Lab scientists discussed seven possible ways to extract plutonium from irradiated uranium, and decided to pursue investigation of all seven. On 17 June, the first batch of uranium nitrate hexahydrate (UNH) was undergoing neutron bombardment in the Washington University in St. Louis cyclotron. On 27 July, the irradiated UNH was ready for Glenn T. Seaborg's team. On 20 August, using ultramicrochemistry techniques, they successfully extracted plutonium. In May 1942, Gertrude Scharff Goldhaber at Brookhaven National Laboratory reports for the first the emission of multiple neutrons during spontaneous fission of uranium. Her research was kept a secret. In April 1939, creating a chain reaction in natural uranium became the goal of Fermi and Szilard, as opposed to isotope separation. Their first efforts involved five hundred pounds of uranium oxide from the Eldorado Radium Corporation. Packed into fifty-two cans two inches in diameter and two feet long in a tank of manganese solution, they were able to confirm more neutrons were emitted than absorbed. However, the hydrogen within the water absorbed the slow neutrons necessary for fission. Carbon in the form of graphite, was then considered, because of its smaller capture cross section. In April 1940, Fermi was able to confirm carbon's potential for a slow-neutron chain reaction, after receiving National Carbon Company's graphite bricks at their Pupin Laboratories.
Sources: en.wikipedia.org
==== Catechol O-methyltransferase (COMT) inhibitors ==== Entacapone (Comtan) – catechol O-methyltransferase (COMT) inhibitor Opicapone (BIA 9-1067; BIA-91067; Ongentys; ONO-2370) – catechol O-methyltransferase (COMT) inhibitor [341] Tolcapone (RO-407592; Tasmar) – catechol O-methyltransferase (COMT) inhibitor [342]
=== Response from political organizations === Health Care Without Harm opposes the use of recombinant bovine growth hormone due to its adverse impacts on animals and potential harm to humans. Oregon Physicians for Social Responsibility recommends buying products from cows not injected with recombinant bovine growth hormone (rBGH or rBST).
=== "Out of Testis" hypothesis === An early case study of de novo gene birth, which identified five de novo genes in D. melanogaster, noted preferential expression of these genes in the testes, and several additional de novo genes were identified using transcriptomic data derived from the testes and male accessory glands of D. yakuba and D. erecta. This is in agreement with other studies that showed there is rapid evolution of genes related to reproduction across a range of lineages, suggesting that sexual selection may play a key role in adaptive evolution and de novo gene birth. A subsequent large-scale analysis of six D. melanogaster strains identified 248 testis-expressed de novo genes, of which ~57% were not fixed. A recent study on twelve Drosophila species additionally identified a higher proportion of de novo genes with testis-biased expression compared to annotated proteome. It has been suggested that the large number of de novo genes with male-specific expression identified in Drosophila is likely due to the fact that such genes are preferentially retained relative to other de novo genes, for reasons that are not entirely clear. Interestingly, two putative de novo genes in Drosophila (Goddard and Saturn) were shown to be required for normal male fertility. A genetic screen of over 40 putative de novo genes with testis-enriched expression in Drosophila melanogaster revealed that one of the de novo genes, atlas, was required for proper chromatin condensation during the final stages of spermatogenesis in male.
For animals like the sand dollar (an echinoderm) their main mode of reproduction is broadcast spawning. An adult sand dollar's sex cannot be determined directly by just looking at it. The only way to determine the sex of the animal is by the color of its gamete exudate. The gamete exudate is the fluid released into the water during the spawning of sand dollars. Yellow exudate will contain eggs and white exudate will contain sperm. By completing reproduction through spawning, sand dollars will reproduce in groups which increases the chances of fertilization. Male sand dollars start spawning by releasing sperm through the accessory papillae or the gonopores. After roughly 10 minutes, spawning stops, and the sand dollar will cover itself with sand. After the male spawns, the sperm enters the female's egg, beginning fertilization. After roughly 80 minutes of fertilization, cell division will begin to occur, also known as cleavage. After cleavage, the cells become blastulae and then gastrula. During the gastrula stage, the embryo's height decreases and the width slightly increases. After the gastrula stage, the larvae will begin the pluteus stage. At this point in a sand dollar's early stages of life, it will want to feed but cannot. The sand dollar larvae will have mouths that are able to open but cannot eat. Along with wanting to feed, the larvae will have three identifiable body parts: an esophagus, stomach, and intestine. Though at the beginning of the pluteus stage, the larvae cannot feed, it will feed towards the end of the stage just before metamorphosis.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.